Woburn, MA, - September 10, 2007 - Collaborators of Nuvera Biosciences from The University of Texas M. D. Anderson Cancer Center reported at the 1st American Society of Clinical Oncology Breast Cancer Symposium Sept. 7-8 in San Francisco that independent genomic tests provide specific information about sensitivity to hormonal therapy, and to a current standard chemotherapy, in order to complement prognostic risk, if untreated.
